2 ml tirzepatide vial Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Tirzepatide Dosing in Units: Master

Injection-site reactions are common (5-10%) but mild

They tend to spike again with each dose increase

In phase 2 trials, orforglipron achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweight, in line with the mid-teens weight reduction from NVOs higher dose oral semaglutide , as well as the injectables currently in the market

The trial was not designed to prove a CV benefit, but to confirm noninferiority of oral semaglutide versus placebo for the primary end point, and was event-driven, requiring 122 MACEs to be accrued to provide sufficient statistical power for noninferiority testing